INMB: INmune Bio, Inc. Stock

by  •  • Comments Off on INMB: INmune Bio, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 177.82
Enterprise Value ($M) 146.77
Book Value ($M) 38.67
Book Value / Share 1.74
Price / Book 4.60
NCAV ($M) 21.74
NCAV / Share 0.98
Price / NCAV 8.18

Profitability (mra)
Return on Invested Capital (ROIC) -0.99
Return on Assets (ROA) -0.72
Return on Equity (ROE) -1.08

Liquidity (mrq)
Quick Ratio 2.59
Current Ratio 2.59

Balance Sheet (mrq) ($M)
Current Assets 35.85
Assets 52.78
Liabilities 14.11
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-15 13G Praetorian PR LLC 5.50
10-25 13G Highbridge Capital Management Llc 6.60
10-02 13G/A Xencor Inc 9.60 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-10-31 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 ☐ TRANSITION REPO
2024-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 ☐ TRANSITION REPORT PU
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 ☐ TRANSITION REPORT P
2024-04-16 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UN
2024-03-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-10 66,430 240,553 27.62
2025-03-07 58,312 154,110 37.84
2025-03-06 76,733 209,675 36.60
2025-03-05 46,985 199,742 23.52

(click for more detail)

Similar Companies
INDP – Indaptus Therapeutics, Inc. INKT – MiNK Therapeutics, Inc.
INM – InMed Pharmaceuticals Inc. INO – Inovio Pharmaceuticals, Inc.
INTS – Intensity Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io